Shopping Cart 0
Cart Subtotal
USD 0

KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018

Summary

This KOL Insight briefing focuses on KOLs views of Pipeline Therapy Data Presented at EULAR 2018.

Questions topics-

- Opinion on abatacept failing to achieve its primary endpoint in its Phase III LN trial

- Views on the Phase III safety data for abatacept in LN

- Expectations regarding abatacept's future development in lupus

- Opinion on ustekinumab's ability to achieve partial improvements using SLEDAI-2K Responder Index-50

- Views on ustekinumab's Phase III trial design

- Views on the absence of safety endpoints in the Phase III ustekinumab trial in SLE

- Perception of etanercept's efficacy in discoid lupus erythematosus

- Opinion on etanercept's safety data from the Phase II TARGET-DLE trial

Key Highlights

- While most KOLs agreed that abatacept's future in LN is uncertain, half of the KOLs highlighted that the drug has potential in lupus arthritis

- Most KOLs highlighted that SLEDAI-2K Responder Index-50 data supports ustekinumab use in SLE

- While most KOLs flagged that etanercept may exacerbate lupus features, half of the KOLs highlighted that etanercept has potential in lupus.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our Lupus key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during Aug 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on Pipeline Therapy Data Presented at EULAR 2018

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Lupus, Phase III, arthritis, nephritis, endpoints


Companies

Janssen

BMS

Pfizer

Merck